Comparative Study of the Free Radical Scavenging Activities of Original and Generic Edaravone Determined by Electron Spin Resonance

Jimbo H1*, Ikeda Y1 and Chang-il Lee M2
1Department of Neurosurgery, Tokyo Medical University Hachiouji Medical Center, Tokyo, Japan
2Division of Pharmacology and ESR laboratories, Department of Clinical Care Medicine, Kanagawa Dental College, Yokosuka, Japan

Abstract

Edaravone, a powerful free radical scavenger, is the drug available in the clinical practice for the treatment of cerebral infarction and amyotrophic lateral sclerosis. Recently, many generic Edaravone injections have been commercialized. Substitution of additives in generic injections has the potential effect of changing the antioxidant ability of the original Edaravone injection. We investigated the dissimilarity between original and generic Edaravone injections focusing on their free radical scavenging activities determined by electron spin resonance spectroscopy. There were no significant differences between the original and generic Edaravone regarding the antioxidant abilities toward the hydroxyl radical. However, the generics in which the additive L-cysteine was substituted with glycerin or citric acid showed significant reduction in their antioxidant activity toward superoxide (p <0.01). Our in vitro findings suggest that the antioxidant ability of generic Edaravone against the hydroxyl radical is equivalent to that of the original Edaravone and that substitution of additives in the generic Edaravone might change its antioxidant activity toward the superoxide.

Keywords: Edaravone; Antioxidant activity; Brain ischemia; Neuroprotectant

Introduction

Oxygen free radical species may play detrimental roles in brain ischemia and edema [1-3], and onset and progression of amyotrophic lateral sclerosis (ALS) [4]. Edaravone (3-methyl-1 phenyl-2-pyrazolin-5-one, MCI-186, Radicut; developed by Mitsubishi Tanabe pharma corporation, Osaka, Japan), a powerful free radical scavenger, is currently used for the treatment of cerebral infarction and ALS [5-8]. It was shown that Edaravone scavenged radicals such as hydroxyl radical (HO•), peroxyl radicals (LO2•), DPPH (1,1-diphenyl-2-picylhydrazyl) radicals, and nitric oxide (NO•) directly [5-7,9]. It was demonstrated that the inhibition of lipid peroxidation by Edaravone was probably due to the scavenging of the chain carrying LO2• and that, in combination with vitamin E or C, the antioxidant activity of Edaravone may be enhanced [7]. In clinical studies, Edaravone improved the core neurological deficits, the activities of daily life, and the functional outcome of stroke patients [10,11].

Recently, over 20 generic Edaravone injections have been put on the market in Japan. The generic injections should keep the same active ingredient; however, this rule cannot be applied to the additives. The additive L-cysteine present in the original Edaravone injections is substituted with citric acid, alpha thioglycerin, or glycine in some generic injections. The additives were changed in 10 generic Edaravone injections among 21 generics that have been approved in Japan in 2011 (Table 1). L-cysteine, citric acid, alpha thioglycerin, and glycine possess free radical scavenging activities, but their antioxidant potency is different. Hence, substitution of additives has the potential of changing the antioxidant ability of the original Edaravone injections.

In the present study, we investigated the dissimilarity between the original and generic Edaravone injections by focusing on their free radical scavenging activities determined by electron spin resonance (ESR) spectroscopy.

Materials and Methods

Reagents

The original Edaravone injection and 6 generic Edaravone injections are analyzed in this study. All the generics have the same active ingredient; however, the additives are different. Two generics employ glucose (A) and citric acid (E) instead of L-cysteine, while the other 4 generics have the same additives (Table 1). Solvents and other reagents are of the highest grade commercially available.

Assay for radical intensity

Superoxide (O2•-) was generated by titanium dioxide (TiO2) photocatalysis, as described previously [12]. HO• was generated by the Fenton’s reaction (H2O2/FeSO4), as described previously [13,14]. Alternatively, HO• could be generated by irradiating H2O2 with ultraviolet light (365 nm UV; 5s ; 40 mW; SUPERCURE-203S, Radical Research, Tokyo, Japan), as described previously [15,16]. All the solutions were prepared in 0.1 M phosphate-buffered saline (PBS) at pH 7.2. ESR spin trapping was conducted using a reactive oxygen species (ROS)-generating system containing 5-(2, 2-dimethyl-1,3-propanoxycyclophosphoryl)-5-methyl-1-pyrroline-N-oxide (CYMPO; Radical Research, Tokyo, Japan). ESR measurements were performed with a JES-RE1X system (JEOL, Tokyo, Japan) connected to the WINDR (ESR Data Analyzer program (Radical Research , Tokyo, Japan), under the following instrument settings: microwave power, 8.00 mW; magnetic field 335.6 ± 7.5 mT; field modulation width, 0.079 mT; sweep time, 1 min; and time constant, 0.03 s. All the experiments were repeated for a minimum of 3 times. Distilled water was used as the control. For each experimental group, the antioxidant activity was calculated as 100% with a mean value of control.

Statistical analysis

Statistical comparisons were made using non-repeated measures.
analysis of variance (ANOVA). Data are expressed as mean ± standard deviation (SD). The statistical significance was set at $p < 0.05$.

**Results**

**Dissimilarity between the original and generic Edaravone on $O_2^-$**

We investigated the antioxidant effect of the original and generic Edaravone on $O_2^-$ generated by TiO₂ photocatalysis using the ESR spin trapping technique with CYMPO. The significant reduction in the antioxidant activity toward $O_2^-$ in the case of 2 generic Edaravone injections compared with that of the original drug was measured ($p < 0.01$). There were no significant differences in the generics in which the additives were equivalent to those of the original injection (generic Edaravone B, C, D and F); however, the generics A and E in which the additive L-cysteine was substituted with glycerin or citric acid respectively showed reduction in their antioxidant activity toward $O_2^-$ (Figure 1).

**Dissimilarity between the original and generic Edaravone on $HO^-$**

We investigated the antioxidant activity of the original and generic Edaravone on $HO^-$ generated by Fenton's reaction or ultraviolet irradiation of $H_2O_2$, using ESR spin trapping with CYMPO. There were no significant differences between the original and generic Edaravone injections (Figures 2 and 3).

**Discussion**

The relationship between ischemic brain injury and lipid peroxidation disorder by free radicals was first described by Flamm et al. in 1978 [2]. Increasing evidence suggests that oxygen free radical species may play detrimental roles in ischemic diseases [1,3,17-19] and ALS [4] and selective free radical scavengers as brain protective agents are considered to be potential drugs against brain ischemia [20] and ALS [8]. Although the world’s first clinical use of Edaravone, which has been developed as a neuroprotectant, was approved in Japan in 2001 [11], it remains under clinical investigation in various other countries [21] and its use has not been approved yet in Western countries. However, Edaravone is recommended by the American Heart Association in the guidelines for the early management of adults with acute ischemic stroke [22]. The administration of Edaravone during Alteprase infusion is likely to enhance the recanalization in patients with acute ischemic stroke [23]. The generic Edaravone injections have been approved in

**Table 1:** Changes of additives in generic Edaravone injections which have been approved in Japan at 2011.

| Additives | sodium hydrogen sulfate | L-cysteine | sodium chloride | sodium hydroxide | phosphoric acid | pH regulating agent | sodium bicarbonate | glycine | citric acid | sodium citrate hydrate | alpha thioglycerin |
|-----------|-------------------------|------------|----------------|-----------------|----------------|-------------------|-------------------|---------|-------------|----------------------|------------------|
| Original  | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| Generics  |                         |            |                |                 |                |                   |                   |         |             |                      |                  |
| A         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| B         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| C         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| D         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| E         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| F         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| H         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| I         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| J         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| K         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| L         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| M         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| N         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| O         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| P         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| Q         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| R         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| S         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| T         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| U         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |
| V         | 0                       | 0          | 0              | 0               | 0              | 0                 | 0                 |         |             | 0                    |                  |

**Figure 1:** Antioxidant activity of the original and generic Edaravone injections toward superoxide ($O_2^-$) generated by TiO₂ photocatalysis reaction calculated using the relative ESR signal intensities. The data are expressed as mean ± standard deviation (SD, n = 9) calculated as 100% with the mean value of distilled water as the control. The additives were substituted from L-cysteine to glycine in A, and to citric acid in E (Table 1). The significant differences compared to the original injection were recognized in A and E. A-F: Generic Edaravone injections which have been made in each pharmaceutical company, DW: distilled water, cont: control, *: Significantly different ($p<0.01$) compared to the original injection
Japan in 2011 and are now produced in several countries such as Korea, India, and China.

The basic chemical structure of Edaravone (3-Methyl-1-phenyl-2-pyrazolin-5-one) was found to show promising activity as an antioxidative radical scavenger, was capable of quenching HO−, which among other oxidative free radicals has the strongest oxidative ability, and could inhibit both HO−-dependent and HO−-independent lipid peroxidation. Furthermore, additional free radical scavenging and antioxidative actions of Edaravone were identified in LOO−-induced peroxidation [7] and peroxynitrite (ONOO−)-induced tyrosine nitration [6,9]. However, this basic chemical structure of Edaravone does not show antioxidant activity for O2•−, which has very low oxidative ability [6]. In our study, the ability of the generic Edaravone as a free radical scavenger for HO− was found to be equivalent to that of the original drug, probing the safety of the basic chemical structure of the generic Edaravone. Therefore, the generic Edaravone drugs have achieved the objective of the development of original Edaravone equally.

Whether Edaravone could scavenge O2•− or not is still controversial [24]. It is known that the thiol group (-SH) of L-cysteine reacts with the DPPH radical and thus scavenges free radicals [25,26]. Consistently, a significant reduction in the O2•− scavenging activity was found only in those generics in which the additive L-cysteine was substituted with glycerin or citric acid. Even though O2•− has low oxidative ability, it is the key radical that initiates other free radical chain reactions. The fact that the substitution of additives affected the scavenging activity of Edaravone for O2•− showed that L-cysteine plays an important role in scavenging O2•− in Edaravone injections. There is a report mentioned that 1mM Edaravone injection suppressed the formation of O2•− in the xanthine oxidase-hypoxanthine system [24]. Therefore, the generic Edaravone injections in which additive L-cysteine has been substituted with another additive have the possibility to reduce its own ability as an antioxidative radical scavenger. However, our study is an in vitro analysis, while the additives injected into the veins are immediately diluted and spread by a large amount of blood; therefore, in vivo, the radical scavenging activity of L-cysteine might disappear. Further in vivo studies are necessary to draw the conclusion that additive changes in generic Edaravone involve the antioxidiant ability in clinical use.

Conclusion

Our in vitro studies suggest that the antioxidant ability of generic Edaravone against the HO− radical is equivalent to that of the original Edaravone and that substitution of additives in the generic Edaravone might change its antioxidant activity toward the O2•−.

Acknowledgments

We gratefully acknowledge Takeo Otsuka, Makiko Saida, Tomoko Komatsu, Ayaka Yoshida, and Fumihiko Yoshino for their excellent technical assistance.

References

1. Demopoulos HB, Flamm ES, Pietronigro DD, Seligman ML (1980) The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand Suppl 492: 91-119.
2. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff JF (1978) Free radicals in cerebral ischemia. Stroke 9: 445-447.
3. Siesjö BK (1981) Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1: 155-185.
4. Beckman JS, Carson M, Smith CD, Koppelen W (1993) ALS, SOD and peroxynitrite. Nature 364: 584.
5. Watanabe K, Yuki S, Saito K, Sato S, Sugimoto J, et al. (1997) Pharmacological studies of MCI-186, a new drug for acute stroke, Jpn Pharmacol Ther 25: 1691-1698.
6. Watanabe K, Watanabe K, Hayase T (1997) Radical scavenging mechanism of MCI-186, Jpn Pharmacol Ther 25: 1699-1707.
7. Yamamoto Y, Kuwahara T, Watanabe K, Watanabe K (1996) Antioxidant activity of 3-methyl-1-2-pyrazoline-5-one. Redox Report 2: 333-338.
8. Abe K, Itoyo Y, Sobue G, Tsuchi M, Aoki K, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15: 610–617.
9. Satoh K, Ikeda I, Shioda S, Tobe T, Yoshikawa T (2002) Edarabone scavenges nitric oxide. Redox Rep 7: 219-222.
10. Edaravone Acute Infarction Study Group (2003) Effect of a novel free radical scavenger, Edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15: 222-229.
11. Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, et al. (1998) Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction: a parallel evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 7: 315-322.
12. Lee MC, Yoshino F, Shoji H, Takahashi S, Todoki K, et al. (2005) Characterization by electron spin resonance spectroscopy of reactive oxygen species generated by titanium dioxide and hydrogen peroxide. J Dent Res 84: 178-182.
13. Hagiwara T, Lee CI, Okabe E (2000) Differential sensitivity to hydroxyl radicals of pre- and postjunctional neurovascular transmission in the isolated canine mesenteric vein. Neuropsychopharmacology 39: 1662-1672.

14. Lee C, Okabe E (1995) Hydroxyl radical-mediated reduction of Ca(2+)-ATPase activity of masseter muscle sarcoplasmic reticulum. Jpn J Pharmacol 67: 21-28.

15. Ogawara Y, Namai T, Yoshino F, Lee MC, Ishii K (2007) Sialic acid is an essential moiety of mucin as a hydroxyl radical scavenger. FEBS Lett 581: 2473-2477.

16. Sakurai K, Sasabe H, Koga T, Konishi T (2004) Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res 38: 487-494.

17. Lewén A, Matz P, Chan PH (2000) Free radical pathways in CNS injury. J Neurotrauma 17: 871-890.

18. Morimoto T, Globus MY, Bustro R, Martinez E, Ginsberg MD (1996) Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 16: 92-99.

19. Peters O, Back T, Lindauer U, Busch C, Megow D, et al. (1998) Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 18: 196-205.

20. Tamura A, Asano T, Sano K, Tsumagari T, Nakajima A (1979) Protection from cerebral ischemia by a new imidazole derivative (Y-9179) and pentobarbital. A comparative study in chronic middle cerebral artery occlusion in cats. Stroke 10: 126-134.

21. Wang CX, Shuaib A (2007) Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 24: 337-346.

22. Adams HP, del Zoppo G, Alberts MJ (2007) Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 22: e478-e534.

23. Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, et al. (2012) Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients—a preliminary study. J Neurol Sci 313: 132-136.

24. Wu TW, Zeng LH, Wu J, Fung KP (2000) MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci 67: 2387-2392.

25. Molyneux P (2004) The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. Songklanakarin J Sci Technol 26: 211-219.

26. Yamaguchi T, Takamura H, Matoba T, Terao J (1998) HPLC method for evaluation of the free radical-scavenging activity of foods by using, 1-diphenyl-2-picrylhydrazyl. Biosci Biotechnol Biochem 62: 1201-1204.